Ayesha Butt,Doruk Erkan,Alfred Ian Lee
Ayesha Butt
Antiphospholipid syndrome and the coagulopathy of COVID-19 share many pathophysiologic features, including endotheliopathy, hypercoagulability, and activation of platelets, complement pathways, and neutrophil extracellular traps, all acting...
Lalitha Nayak,Ze Zheng
Lalitha Nayak
Lynne Strasfeld
Lynne Strasfeld
HSCT recipients are at increased risk for COVID-19-associated morbidity and mortality. Early treatment of symptomatic SARS-CoV-2 infection is an important means to decreasing risk for severe disease and death. While some HSCT recipients, pa...
Ethan Davitt,Colin Davitt,Monty B Mazer et al.
Ethan Davitt et al.
The SARS-CoV-2 virus has complex and divergent immune alterations in differing hosts and over disease evolution. Much of the nuanced COVID-19 disease immune dysregulation was originally dominated by innate cytokine changes, which has since ...
A perspective on the sickle cell disease international COVID-19 registry [0.03%]
镰状细胞疾病国际COVID-19登记册的观点
Lana Mucalo,Amanda M Brandow,Ashima Singh
Lana Mucalo
To understand the risks and outcomes of COVID-19 in the sickle cell disease (SCD) population, our team established a rapid reporting registry to collect data on the course of COVID-19 illness in individuals with SCD. The registry includes c...
Adam J Kanack,Anand Padmanabhan
Adam J Kanack
Vaccine-induced immune thrombotic thrombocytopenia (VITT) is primarily a complication of adenoviral vector-based covid-19 vaccination. In VITT, thrombocytopenia and thrombosis mediated by anti-platelet factor 4 (PF4) antibodies can be sever...
Heng Zhang,Qifang Lao,Jue Zhang et al.
Heng Zhang et al.
Severe acute respiratory disease coronavirus 2 (SARS-COV-2) first emerged in Wuhan, China, in December 2019 and has caused a global pandemic of a scale unprecedented in the modern era. People infected with SARS-CoV-2 can be asymptomatic, mo...
Martha M S Sim,Jeremy P Wood
Martha M S Sim
Coronavirus Disease 2019 (COVID-19) has been widely associated with increased thrombotic risk, with many different proposed mechanisms. One such mechanism is acquired deficiency of protein S (PS), a plasma protein that regulates coagulation...
Prevention and treatment of COVID-19 in patients with benign and malignant blood disorders [0.03%]
COVID-19在良性及恶性血液疾病患者中的预防和治疗
Elie A Saade,Leila S Hojat,Praveen Gundelly et al.
Elie A Saade et al.
Patients with moderate to severe immunosuppression, a condition that is common in many hematologic diseases because of the pathology itself or its treatment, are at high risk for COVID-19 and its complications. While empirical data are some...
Moua Yang
Moua Yang
COVID-19 is the respiratory illness caused by the beta coronavirus SARS-CoV-2. COVID-19 is complicated by an increased risk for adverse thrombotic events that promote organ failure and death. While the mechanism of action for SARS-CoV-2 is ...